Basilea Pharmaceutica AG

Basilea Pharmaceutica AG

BPMUF - Insider Information

Get informed when a big investor buys or sells

+ Follow
Market Cap$1.04B
Close$

Compare to Similar Companies

P/E RatioDividendsReturn on EquityPrice-to-SalesDebt-to-Equity
Basilea Pharmaceutica AGBasilea Pharmaceutica AG17.1-72%2.50.5
$66.70

Current Fair Value

20.6% downside

Overvalued by 20.6% based on the discounted cash flow analysis.

Insider Trades

Loading insider trades…

Congress Trades

Loading congress trades…

Share Statistics

Market cap$1.04 Billion
Enterprise Value$948.14 Million
Earnings per Share$3.29
Beta0.41
Outstanding Shares12,370,195

Return

Return on Equity72.13%ROE
Return on Assets39.29%
Return on Invested Capital48.13%

Valuation & Multiples

P/E Ratio17.07P/E Ratio
PEG6.73PEG
Price to Sales2.47Price to Sales
Price to Book Ratio6.46Price to Book Ratio
Enterprise Value to Revenue2.2
Enterprise Value to EBIT7.68
Enterprise Value to Net Income8
Total Debt to Enterprise0.09
Debt to Equity0.52Debt to Equity

Revenue Sources

No data

Last Earnings Call

Report Date
August 18, 2026
EPS
$2.64
Est. $4.14
Revenue
$147.21 M
Est. $133.24 M

Next Earnings Call

Expected Date
February 16, 2027
EPS Estimate
$7.02
Consensus analyst estimate
Revenue Estimate
$212.13 M
Consensus analyst estimate

Institutional Sentiment (Put/Call)

No data available for the latest quarter.

Institutional Ownership

No data available for the latest quarter.

About Basilea Pharmaceutica AG

189 employees
CEO: David Veitch

Basilea Pharmaceutica AG is a revenue-generating biopharmaceutical company dedicated to developing innovative products to meet critical medical needs in both cancer treatment (oncology) and the fight against infections (anti-infectives)....